SCHEMBL2669746

SCHEMBL2669746

CCCCOCCCOc1ccc(CC(C(=O)OC)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.50
▸ ESR2 Q92731 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ HRH3 Q9Y5N1 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ GCGR P47871 2/20 0.42
▸ ACACB O00763 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MITF O75030 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ ADCY6 O43306 1/20 0.42
▸ ADCY3 O60266 1/20 0.42
▸ ADCY9 O60503 1/20 0.42
▸ ADCY5 O95622 1/20 0.42
▸ ADCY8 P40145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669616 0.97 ESR1 (0.49) ESR1ESR2ALDH1A1LMNAMEN1
SCHEMBL2669617 0.96 ESR1 (0.54) ESR1ESR2ALDH1A1LMNAMEN1
SCHEMBL11999235 0.91 ESR1 (0.54) ESR1ESR2ALDH1A1LMNAMEN1
SCHEMBL2669728 0.89 LMNA (0.50) ALDH1A1LMNAMEN1KMT2AHRH3
SCHEMBL2656926 0.88 KMT2A (0.53) ESR1ESR2ALDH1A1LMNAMEN1
SCHEMBL2669618 0.86 LMNA (0.49) ALDH1A1LMNAMEN1KMT2AHRH3
SCHEMBL11999238 0.84 LMNA (0.54) LMNAKMT2ASMN1; SMN2KDM4EPOLB
SCHEMBL2659405 0.82 KMT2A (0.53) ESR1ESR2ALDH1A1LMNAMEN1
SCHEMBL2658018 0.80 KMT2A (0.58) ESR1ESR2ALDH1A1LMNAMEN1
SCHEMBL2669629 0.79 LMNA (0.50) ALDH1A1LMNAKMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 — — US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 — — US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 — — US disclosed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 — — EP disclosed
EP-2129654-B1 ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2014-05-28 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback